A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Berenson Cancer Center- Site Number : 8400044, West Hollywood, California +15 locations
Conditions: Plasma Cell Myeloma Refractory
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
Recruiting
This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. Participants will receive a single administration of NGGT002 and will be followed for safety and efficacy for 5 years.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/07/2025
Locations: University of Minnesota, Minneapolis, Minnesota +3 locations
Conditions: Phenylketonurias
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Recruiting
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Los Angeles Cancer Network, Los Angeles, California +113 locations
Conditions: Recurrent or Metastatic Solid Tumors
Writing Intervention With Adolescents and Young Adults With Cancer
Recruiting
Young people with cancer have difficult experiences and writing exercises may help improve their well-being. However, very few studies have examined how a creative writing activity might be useful for young people with cancer. In this pilot study, researchers at St. Jude Children's Research Hospital hope to explore whether teenagers and young adults with cancer want to participate in a writing exercise and whether they find it to be valuable. Primary Objective To assess the feasibility and acc... Read More
Gender:
ALL
Ages:
Between 15 years and 25 years
Trial Updated:
08/07/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Cancer Patients, Communication Research
Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically
Recruiting
Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to H... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: HIV Infections
National Liver Cancer Screening Trial
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/07/2025
Locations: University of Southern California, Los Angeles, California +16 locations
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
08/07/2025
Locations: Banner University, Phoenix, Arizona +83 locations
Conditions: Atrial Fibrillation
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Recruiting
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma. This treatment will be carried out in addition to the maximal surgical resection. Data collected during this trial will be used to design the upcoming pivotal study . The study will utilize an independent Data and Safety Monitori... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: UPMC Hillman Cancer center, Pittsburgh, Pennsylvania +1 locations
Conditions: Primary Glioblastoma
Confronting Cancer as a Community
Recruiting
This study aims to better understand the cause of colorectal cancer and how to find the best treatment for Hispanic patients with colorectal cancer. The genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. By combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to diffe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Los Angeles County-USC Medical Center, Los Angeles, California +1 locations
Conditions: Colorectal Carcinoma
F15 Recharge Free Axonics SNM System Clinical Study
Recruiting
Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Hartford Healthcare, Waterford, Connecticut +15 locations
Conditions: Urinary Urge Incontinence (UUI), Fecal Incontinence (FI), Urinary Frequency (UF)
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Recruiting
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments. Primary Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pe... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
08/07/2025
Locations: University of Colorado Hospital, Aurora, Colorado +3 locations
Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Optional Open Label Extension: 104 weeks Safety follow-up:... Read More
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
08/07/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400012, San Francisco, California +73 locations
Conditions: Type 1 Diabetes Mellitus